SA519410025B1 - مثبطات ديميثيلاز-1 نوعي لللايسين - Google Patents

مثبطات ديميثيلاز-1 نوعي لللايسين

Info

Publication number
SA519410025B1
SA519410025B1 SA519410025A SA519410025A SA519410025B1 SA 519410025 B1 SA519410025 B1 SA 519410025B1 SA 519410025 A SA519410025 A SA 519410025A SA 519410025 A SA519410025 A SA 519410025A SA 519410025 B1 SA519410025 B1 SA 519410025B1
Authority
SA
Saudi Arabia
Prior art keywords
compositions
inhibitors
specific demethylase
lysine specific
compounds
Prior art date
Application number
SA519410025A
Other languages
English (en)
Inventor
كانوني توفيكي
الآن ستافورد جيفري
مارفين فيال جيمس
دبليو. كالدور ستيفن
كي تشين يانج
Original Assignee
سلجين كوانتيسيل ريسيرتش، انك.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by سلجين كوانتيسيل ريسيرتش، انك. filed Critical سلجين كوانتيسيل ريسيرتش، انك.
Publication of SA519410025B1 publication Critical patent/SA519410025B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polyamides (AREA)

Abstract

يتعلق الاختراع الحالي بشكل عام بتركيبات وطرق لعلاج السرطان treating cancer ومرض نمو ورمي neoplastic disease. يتم في هذا الطلب توفير مركبات من مشتق غير متجانس حلقيًا به استبدال وتركيبات صيدلانية تشتمل على المركبات المذكورة. تعد المركبات والتركيبات الخاصة بالاختراع مفيدة في تثبيط إنزيم ديميثيلاز-1 specific demethylase-1 نوعي لللايسين lysine. علاوة على ذلك، تعد المركبات والتركيبات الخاصة بالاختراع مفيدة في علاج السرطان cancer.
SA519410025A 2014-05-01 2016-10-31 مثبطات ديميثيلاز-1 نوعي لللايسين SA519410025B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461987354P 2014-05-01 2014-05-01
PCT/US2015/028635 WO2015168466A1 (en) 2014-05-01 2015-04-30 Inhibitors of lysine specific demethylase-1

Publications (1)

Publication Number Publication Date
SA519410025B1 true SA519410025B1 (ar) 2022-06-01

Family

ID=54354743

Family Applications (2)

Application Number Title Priority Date Filing Date
SA516380201A SA516380201B1 (ar) 2014-05-01 2016-10-31 مثبطات ديميثيلاز-1 نوعي لللايسين
SA519410025A SA519410025B1 (ar) 2014-05-01 2016-10-31 مثبطات ديميثيلاز-1 نوعي لللايسين

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SA516380201A SA516380201B1 (ar) 2014-05-01 2016-10-31 مثبطات ديميثيلاز-1 نوعي لللايسين

Country Status (31)

Country Link
US (9) US9255097B2 (ar)
EP (1) EP3137169B1 (ar)
JP (1) JP6493890B2 (ar)
KR (1) KR102400920B1 (ar)
CN (1) CN106659914B (ar)
AR (1) AR100251A1 (ar)
AU (1) AU2015253040B2 (ar)
BR (1) BR112016025248B1 (ar)
CA (1) CA2947283C (ar)
CL (1) CL2016002736A1 (ar)
CY (1) CY1124959T1 (ar)
DK (1) DK3137169T3 (ar)
EA (1) EA036672B8 (ar)
ES (1) ES2903423T3 (ar)
HR (1) HRP20220096T1 (ar)
HU (1) HUE057895T2 (ar)
IL (1) IL248505B (ar)
LT (1) LT3137169T (ar)
MX (1) MX2016014253A (ar)
NI (1) NI201600165A (ar)
PE (1) PE20161438A1 (ar)
PH (1) PH12016502179A1 (ar)
PL (1) PL3137169T3 (ar)
PT (1) PT3137169T (ar)
RS (1) RS62874B1 (ar)
SA (2) SA516380201B1 (ar)
SG (1) SG11201609033TA (ar)
SI (1) SI3137169T1 (ar)
TW (1) TWI676620B (ar)
WO (1) WO2015168466A1 (ar)
ZA (1) ZA201607613B (ar)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3094629B1 (en) 2014-01-17 2018-08-22 Novartis AG 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
US10093646B2 (en) 2014-01-17 2018-10-09 Novartis Ag 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2
AR100251A1 (es) 2014-05-01 2016-09-21 Celgene Quanticel Res Inc Inhibidores de la dematilasa-1 especifica de lisina
PT3511319T (pt) * 2014-07-03 2023-06-29 Celgene Quanticel Res Inc Inibidores de desmetilase-1 específica da lisina
MX2017015922A (es) 2015-06-12 2018-12-11 Oryzon Genomics Sa Biomarcadores asociados con inhibidores de lsd1 y usos de los mismos.
EP3310771B1 (en) * 2015-06-19 2020-07-22 Novartis AG Compounds and compositions for inhibiting the activity of shp2
ES2805232T3 (es) 2015-06-19 2021-02-11 Novartis Ag Compuestos y composiciones para inhibir la actividad de SHP2
EP3310779B1 (en) 2015-06-19 2019-05-08 Novartis AG Compounds and compositions for inhibiting the activity of shp2
WO2017013061A1 (en) 2015-07-17 2017-01-26 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
US10059668B2 (en) 2015-11-05 2018-08-28 Mirati Therapeutics, Inc. LSD1 inhibitors
LT3371152T (lt) 2015-11-05 2021-04-12 Celgene Quanticel Research, Inc. Kompozicijos, apimančios lizinui specifinės demetilazės-1 inhibitorių, turinčios pirimidino žiedą, ir jų panaudojimas vėžio gydymui
TWI679195B (zh) * 2015-11-27 2019-12-11 日商大鵬藥品工業股份有限公司 新穎聯苯化合物或其鹽
CA3009805C (en) 2015-12-29 2023-10-17 Mirati Therapeutics, Inc. Lsd1 inhibitors
IL261721B (en) 2016-03-15 2022-07-01 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of solid tumors
EP3430015A1 (en) 2016-03-16 2019-01-23 Oryzon Genomics, S.A. Methods to determine kdm1a target engagement and chemoprobes useful therefor
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
MX2018015625A (es) 2016-06-14 2019-03-06 Novartis Ag Compuestos y composiciones para inhibir la actividad de shp2.
MX2019001608A (es) * 2016-08-10 2019-08-29 Celgene Corp Tratamiento de tumores y linfomas no de hodgkin solidos, reincididos y/o refractarios.
EP3523290A4 (en) * 2016-09-30 2020-07-29 Novartis AG IMPROVED EFFICIENCY IMMUNE EFFICIENT CELL THERAPIES
US20190256929A1 (en) 2016-11-03 2019-08-22 Oryzon Genomics, S.A. Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents
EP3535420A1 (en) 2016-11-03 2019-09-11 Oryzon Genomics, S.A. Biomarkers for determining responsiveness to lsd1 inhibitors
AU2018207464B2 (en) 2017-01-10 2020-05-14 Novartis Ag Pharmaceutical combination comprising an ALK inhibitor and a SHP2 inhibitor
US20200039938A1 (en) 2017-03-30 2020-02-06 Albert-Ludwigs-University Freiburg Kdm4 inhibitors
MA50466A (fr) * 2017-05-26 2020-09-02 Taiho Pharmaceutical Co Ltd Nouveau composé de biphényle ou sel de celui-ci
PT3632443T (pt) * 2017-05-26 2023-08-31 Taiho Pharmaceutical Co Ltd Potenciador de efeito antitumoral que utiliza um composto de bifenilo
TWI749235B (zh) 2017-05-31 2021-12-11 日商大鵬藥品工業股份有限公司 基於insm1表現之lsd1抑制劑之治療效果的預測方法
SG11202000077RA (en) 2017-08-03 2020-02-27 Oryzon Genomics Sa Methods of treating behavior alterations
AU2019239658A1 (en) * 2018-03-21 2020-11-12 Suzhou Puhe BioPharma Co., Ltd. SHP2 inhibitors and uses thereof
CN109668987A (zh) * 2019-02-27 2019-04-23 浙江华贝药业有限责任公司 一种3-氨基哌啶二盐酸盐对映异构体测定分析方法
JP7535797B2 (ja) 2019-03-20 2024-08-19 オリソン ヘノミクス，ソシエダ アノニマ 化合物バフィデムスタット（ｖａｆｉｄｅｍｓｔａｔ）などｋｄｍ１ａ阻害剤を使用した注意欠陥多動性障害の処置方法
CA3130638A1 (en) 2019-03-20 2020-09-24 Oryzon Genomics, S.A. Methods of treating borderline personality disorder
CA3143719A1 (en) 2019-06-20 2020-12-24 Celgene Quanticel Research, Inc. Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome
CN114341366A (zh) 2019-07-05 2022-04-12 奥莱松基因组股份有限公司 用于使用kdm1a抑制剂个体化治疗小细胞肺癌的生物标志物和方法
EP4038054A1 (en) * 2019-10-01 2022-08-10 Bayer Aktiengesellschaft Pyrimidinedione derivatives
US20230089536A1 (en) 2020-03-06 2023-03-23 Celgene Quanticel Research, Inc. Combination of an lsd-1 inhibitor and nivolumab for use in treating sclc or sqnsclc
JP2023529367A (ja) 2020-06-05 2023-07-10 セルジーン・クオンティセル・リサーチ・インコーポレイテッド 前立腺がんの治療方法
US20240216357A1 (en) * 2021-03-24 2024-07-04 Sichuan Huiyu Pharmaceutical Co., Ltd. Polycyclic compound and application thereof
JP2024513260A (ja) 2021-04-08 2024-03-22 オリゾン ジェノミックス ソシエダッド アノニマ 骨髄癌処置のためのｌｓｄ１阻害剤の組み合わせ
WO2023217784A1 (en) 2022-05-09 2023-11-16 Oryzon Genomics, S.A. Methods of treating nf1-mutant tumors using lsd1 inhibitors
WO2023217758A1 (en) 2022-05-09 2023-11-16 Oryzon Genomics, S.A. Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors
WO2024110649A1 (en) 2022-11-24 2024-05-30 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer
US11993580B1 (en) 2022-12-02 2024-05-28 Neumora Therapeutics, Inc. Methods of treating neurological disorders

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5550147A (en) * 1992-02-05 1996-08-27 Fujisawa Pharmaceutical Co., Ltd. Pyrazole derivatives, processes for preparation thereof and pharmaceutical composition comprising the same
ATE274510T1 (de) * 1998-06-19 2004-09-15 Chiron Corp Glycogen synthase kinase 3 inhibitoren
JP2005500294A (ja) * 2001-06-19 2005-01-06 ブリストル−マイヤーズ　スクイブ　カンパニー ホスホジエステラーゼ７に対するピリミジン阻害剤
ATE527250T1 (de) 2002-11-21 2011-10-15 Novartis Ag 2,4,6-trisubstituierten pyrimidinen als phosphotidylinositol (pi) 3-kinase inhibitoren und deren verwendung zur behandlung von krebs
US7183287B2 (en) * 2003-04-03 2007-02-27 Pharmacia Corporation Substituted pyrimidinones
TW200526641A (en) * 2003-12-26 2005-08-16 Daiichi Seiyaku Co Amidopyrazole derivatives
AU2007332143B2 (en) 2006-12-11 2012-11-08 Bionomics Limited Chemical compounds and processes
HUE029837T2 (en) 2008-07-29 2017-04-28 Boehringer Ingelheim Int 5-alkynyl pyrimidines
TWI435874B (zh) * 2008-10-31 2014-05-01 Toray Industries 環己烷衍生物及其醫藥用途
US9365539B2 (en) * 2010-05-11 2016-06-14 Merck Sharp & Dohme Corp. Prolylcarboxypeptidase inhibitors
US9527805B2 (en) 2010-09-10 2016-12-27 Robert A. Casero Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders
PE20141322A1 (es) 2011-03-25 2014-10-05 Glaxosmithkline Intellectual Property (N 2) Limited Ciclopropilaminas como inhibidores de desmetilasa 1 especifica de lisina
WO2013175789A1 (ja) 2012-05-24 2013-11-28 出光興産株式会社 有機エレクトロルミネッセンス素子用材料、及びそれを用いた有機エレクトロルミネッセンス素子
TW201444843A (zh) 2013-03-11 2014-12-01 Abbvie Inc 溴區結構域蛋白抑制劑
WO2015018522A1 (en) 2013-08-06 2015-02-12 Oncoethix Sa Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl)
EP3057586B1 (en) 2013-10-18 2019-12-04 Celgene Quanticel Research, Inc. Bromodomain inhibitors
HUE061252T2 (hu) * 2013-12-11 2023-05-28 Celgene Quanticel Res Inc Lizinspecifikus demetiláz-1 inhibítorok
AR100251A1 (es) * 2014-05-01 2016-09-21 Celgene Quanticel Res Inc Inhibidores de la dematilasa-1 especifica de lisina
US20160022684A1 (en) 2014-07-25 2016-01-28 Pharmacyclics Llc Bet inhibitor and bruton's tyrosine kinase inhibitor combinations
CA2966452A1 (en) 2014-12-17 2016-06-23 Samuel David Brown Substituted bicyclic compounds as bromodomain inhibitors
LT3371152T (lt) * 2015-11-05 2021-04-12 Celgene Quanticel Research, Inc. Kompozicijos, apimančios lizinui specifinės demetilazės-1 inhibitorių, turinčios pirimidino žiedą, ir jų panaudojimas vėžio gydymui

Also Published As

Publication number Publication date
HUE057895T2 (hu) 2022-06-28
WO2015168466A8 (en) 2016-11-24
LT3137169T (lt) 2022-04-11
PT3137169T (pt) 2022-01-25
SA516380201B1 (ar) 2019-11-20
JP6493890B2 (ja) 2019-04-03
US20170349555A1 (en) 2017-12-07
CN106659914B (zh) 2020-06-19
SG11201609033TA (en) 2016-11-29
US20200231549A1 (en) 2020-07-23
ES2903423T3 (es) 2022-04-01
ZA201607613B (en) 2017-11-29
US9771329B2 (en) 2017-09-26
US10207999B2 (en) 2019-02-19
US20170114024A1 (en) 2017-04-27
US9255097B2 (en) 2016-02-09
BR112016025248A2 (pt) 2018-06-19
EA036672B8 (ru) 2021-01-13
AU2015253040B2 (en) 2020-04-09
EA036672B1 (ru) 2020-12-07
US20160152595A1 (en) 2016-06-02
KR102400920B1 (ko) 2022-05-20
CA2947283C (en) 2023-01-24
CN106659914A (zh) 2017-05-10
US10023543B2 (en) 2018-07-17
NI201600165A (es) 2017-03-13
US11987560B2 (en) 2024-05-21
AU2015253040A1 (en) 2016-11-24
US20160130247A1 (en) 2016-05-12
PH12016502179A1 (en) 2017-02-13
CL2016002736A1 (es) 2017-06-23
EP3137169A1 (en) 2017-03-08
IL248505A0 (en) 2016-12-29
MX2016014253A (es) 2017-02-08
US11084793B2 (en) 2021-08-10
EA201692079A1 (ru) 2017-04-28
AU2015253040A8 (en) 2017-06-15
DK3137169T3 (da) 2022-02-14
TW201623254A (zh) 2016-07-01
RS62874B1 (sr) 2022-02-28
US20220153706A1 (en) 2022-05-19
PL3137169T3 (pl) 2022-02-28
KR20160144506A (ko) 2016-12-16
US20150315187A1 (en) 2015-11-05
IL248505B (en) 2021-01-31
NZ725914A (en) 2023-09-29
US10654810B2 (en) 2020-05-19
HRP20220096T1 (hr) 2022-04-15
BR112016025248B1 (pt) 2022-12-13
CY1124959T1 (el) 2023-01-05
AR100251A1 (es) 2016-09-21
WO2015168466A1 (en) 2015-11-05
EP3137169A4 (en) 2018-01-10
JP2017514830A (ja) 2017-06-08
US9573930B2 (en) 2017-02-21
CA2947283A1 (en) 2015-11-05
US20170349556A1 (en) 2017-12-07
PE20161438A1 (es) 2017-01-18
EP3137169B1 (en) 2021-11-10
US20180325900A1 (en) 2018-11-15
TWI676620B (zh) 2019-11-11
SI3137169T1 (sl) 2022-04-29
US9776974B2 (en) 2017-10-03

Similar Documents

Publication Publication Date Title
PH12016502179A1 (en) Inhibitors of lysine specific demethylase-1
MX2017002824A (es) Inhibidores demetilasa-1 especifica de lisina.
MX2017000179A (es) Inhibidores de demetilasa-1 especifica de lisina.
MX2020010496A (es) Inhibidores de desmetilasa-1 especifica de lisina.
MX2017000168A (es) Inhibidores de demetilasa-1 especifica de lisina.
HK1247922A1 (zh) 用於治療癌症的吲哚胺2，3-雙加氧酶抑制劑
PH12017501888A1 (en) Bromodomain inhibitor
PH12018500899A1 (en) Compositions and methods for inhibiting arginase activity
MX2017000170A (es) Inhibidores de demetilasa-1 especifica de lisina.
PH12016500722A1 (en) Bromodomain inhibitors
SA515360657B1 (ar) مثبطات ديميثيلاز هيستون
TW201613882A (en) Histone demethylase inhibitors
MX2017000450A (es) Compuestos terapeuticos inhibidores.
MX2017003464A (es) Inhibidores de histona desmetilasa.
MX2017003463A (es) Inhibidores de histona desmetilasa.
EA201892188A1 (ru) Соединения пирролотриазина в качестве ингибиторов tam
MX2017007655A (es) Compuestos para tratar el cancer.